nanozyme drug cenyx

Kolon TissueGene Inc., the cell therapies unit of South Korean pharmaceutical company Kolon Life Science Inc., said on Dec. 28 it has resumed admi...

South Korea’s HK inno.N Corp. has signed a 640 billion won ($540 million) contract to license out its technology for K-CAB, a gastroesophageal...

MedPacto Inc., a South Korean biotechnology company that develops therapeutics for cancer and autoimmune diseases, has agreed with global drugmaker ...

South Korea’s Celltrion Inc. has long been a biosimilar player, producing replicas of original drugs, a growing market in the pandemic era.Ear...

Samsung Bioepis Co., a leading South Korean biopharmaceutical company, has received approval from the US Food and Drug Administration for its Byoovi...

A number of new rare disease treatments, approved in South Korea over the past year, are still unaffordable for the public because of their price ta...

South Korea’s Samsung Biologics Co. is gearing up for the drug substance (DS) sector of the messenger ribonucleic acid (mRNA)-based COVID-19 v...

South Korea-based Daewoong Pharmaceutical Co. is hoping to achieve 5 trillion won ($4.4 billion) in sales by 2027, meaning that the company aims to ...

The rise of the platform economy is a global phenomenon. The spread of the coronavirus pandemic has accelerated the use of contactless technology an...

South Korea’s SK Biopharmaceuticals Co. said on Friday it aspires to become one of the world’s top 10 healthcare companies by 2030 with ...

Eyegene Inc. will be South Korea’s first vaccine maker to conduct clinical tests of messenger ribonucleic acid (mRNA) COVID-19 vaccines. Ealie...

South Korean biosimilar maker Celltrion Inc. and Mirae Asset Group have agreed to an investment that will render them the top shareholder in Iksuda ...

Samsung Biologics will be entering the drug substance segment of the COVID-19 vaccine contract manufacturing business. According to industry sources...

SK Holdings Co., the holding company of South Korean conglomerate SK Group, has become the first Korean company to foray into the targeted protein d...

Biosimilar maker Celltrion Inc. has agreed to develop a tablet-type treatment for autoimmune diseases jointly with the UK biotech startup Intract Phar...

Celleron Therapeutics Ltd., a cancer treatment developer founded by Oxford University professors, is poised to attract $26 million from South Korean a...

Hanmi Pharmaceutical said on Monday that it had signed an agreement with Euclid Medical Products, a company specializing in manufacturing drug dis...